121P - Serum carcinoembryonic antigen levels predicts the efficacy of EGFR-TKI in non-small cell lung cancer harboring EGFR mutations

Date 17 April 2015
Event ELCC 2015
Session Poster lunch
Topics Non-Small-Cell Lung Cancer, Metastatic
Translational Research
Presenter Yanwei Zhang
Citation Annals of Oncology (2015) 26 (suppl_1): 29-44. 10.1093/annonc/mdv050
Authors Y. Zhang1, B. Han1, B. Jin1, Y. Lou1, R. Li1, X. Zhang1, S. Hu2
  • 1Department Of Pulmonary, Shanghai Chest Hospital, 200030 - Shanghai/CN
  • 2Central Laboratory, Shanghai Chest Hospital, 200030 - Shanghai/CN

Abstract

Aim/Background

The purpose of the present study was to find whether the baseline CEA levels were associated with the efficacy of EGFR-TKI in patients harboring EGFR mutations.

Methods

Clinical features, serum tumor marker levels, and survival time were analysed, retrospectively, in 200 non-small cell lung cancer (NSCLC) patients harboring EGFR mutations treated with EGFR-TKI.

Results

The total objective response rate was 44.0%, disease control rate iwa 84.5%. The disease control rate in the patients with high CEA levels was significantly higher than that with low CEA levels (88.3% vs 74.5%, P = 0.029). There was no significant difference in progression free survival (PFS) between high (≥5 ng/ml) and normal CEA groups (<5 ng/ml; 12.0m vs 8.3m, P = 0.055). The PFS in patients with higher CEA levels (≥20 ng/ml) was longer than in patients with lower CEA levels (<20 ng/ml; 12.8m vs 8.7m, P = 0.016). Multivariate analysis shows that high CEA levels (>20ng/ml) were independent predictive factors for PFS (HR = 1.412, 93% CI: 1.042-1.913, P = 0.026).

Conclusions

Baseline serum CEA levels can serve as predictive factors for the treatment of EGFR-TKI in NSCLC patients harboring EGFR mutations.

Disclosure

All authors have declared no conflicts of interest.